MedTrace Logo

Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone

NCT02532634 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2018-05-11

No results posted yet for this study

Summary

The purpose of this study is to compare the anti-emetic effect of ramosetron plus aprepitant and dexamethasone with palonosetron plus aprepitant and dexamethasone in patients receiving highly emetogenic chemotherapy.

Conditions

Interventions

DRUG

ramosetron, aprepitant, dexamethasone

ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4

DRUG

palonosetron, aprepitant, dexamethasone

palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4

Sponsors & Collaborators

  • The Catholic University of Korea

    collaborator OTHER

  • Astellas Pharma Korea, Inc.

    collaborator INDUSTRY

  • Kangdong Sacred Heart Hospital

    lead OTHER

Principal Investigators

  • Jin-Hyoung Kang, Ph.D · The Catholic University of Korea

  • Jung Hye Kwon, PhD · Kangdong Sacred Heart Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-19
Primary Completion
2018-05-08
Completion
2018-05-08

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02532634 on ClinicalTrials.gov